written by reader JEFF BROWN RECENT TEASER

By alas, April 27, 2020

FOR EXPONENTIAL TECH, regarding a small biotech:
”In July 2018, this biotech announced positive results for its Phase 1 clinical trials. And get this. This drug has been used for many years in Japan with few adverse side effects.
Because of this, the FDA granted the drug a qualified infectious disease product designation. In other words, the FDA allowed the company to skip Phase 2 trials and move directly into Phase 3.”
”It’s 2020… and antibacterial infections are killing people at a rate similar to the Middle Ages.
Yet we’re using antibiotics made in the 1980s to treat them. These antibiotics are terribly ineffective today. Even dangerous to rely on.
The CDC warns that 2.8 million Americans will be affected just this year.
It’s why the FDA fast-tracked the approval of the most powerful antibiotic in nearly 40 years.”

Any idea what company this is?

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345